1111111111

#PNS2027

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Featured Mini-Symposia

Choose one of two concurrent sessions.

As part of the 2027 PNS Annual Meeting, attendees may choose from two concurrent Mini-Symposia featuring in-depth exploration of emerging research, clinical advances, and evolving concepts in peripheral neuropathy. Each session brings together leading experts for focused presentations and discussion. Learn more about the topics and speakers below and plan your symposium experience.

Mini-Symposium A

Immuno-Oncology Associated Neuropathies: From Deep Phenotyping to Mechanisms and Precision Diagnostics and Therapeutics

Modern cancer therapy increasingly exposes peripheral nerves to overlapping toxic and immune injury. Cytotoxic chemotherapy, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs) and combination regimens can produce neuropathy, yet attribution determines whether anticancer therapy is modified and whether immunosuppression is initiated. This mini-symposium links oncology, translational neuroimmunology and peripheral nerve medicine. Dan Olson will discuss the transition from chemotherapy to immunotherapy and combinations, future neuropathy burden, referral thresholds and oncological trade-offs. Louisa Müller-Miny will examine why checkpoint release causes tissue-specific nerve injury, how acute inflammatory mechanisms can be distinguished from pre-existing or treatment-related toxic neuropathy, and how longitudinal fluid, tissue, single-cell and experimental approaches may enable prediction and prevention. Aisling Carr will address phenotype-first diagnosis, neurophysiology, biomarkers, standardized neuropathology, treatment and multidisciplinary services. The panel will define priorities for multicentre studies and future oncotherapeutic neurotoxicity surveillance worldwide, with relevance to prevention, survivorship and global access.

Daniel Olson, MD

Daniel Olson, MD

University of Chicago, Chicago, IL, USA

Oncology in Transition: Neuropathy Risk, Attribution and Treatment Trade-Offs

Session Details • Bio

Louisa Müller-Miny, MD

Louisa Müller-Miny, MD

University Hospital Münster, Münster, Germany

From Checkpoint Release to Nerve Injury: Mechanistic Lessons from Immuno-Oncology

Session Details • Bio

Aisling Carr, MD

Aisling Carr, MD

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK

Defining ICI-Associated Neuropathy: Current Clinical Phenotyping and Standardized Neuropathology

Session Details • Bio

Mini-Symposium B

Precision Therapeutics for the Peripheral Nervous System: Targeting, Delivery, and Engineering

This session focuses on targeted strategies for treating pain and neuropathy. Talks will highlight recent advances in basic science, including with adeno-associated viral delivery vectors, engineered structural biology, and newly identified nerve-associated targets. The session will appeal to a broad scientific and clinical audience, with a focus that spans from molecular pathways to translational considerations and implications. Speakers include both tenure-track junior faculty and established senior investigators, and talks will be accessible and of interest to students, postdoctoral researchers, and faculty.

Afrooz Rashnonejad, PhD

Afrooz Rashnonejad, PhD

The Ohio State University, Columbus, OH, USA

A Mutation-Agnostic AAV9 Knockdown-and-Replacement Strategy Rescues Disease Phenotypes in CMT1B Mice

Session Details • Bio

Michael Caterina, MD, PhD

Michael Caterina, MD, PhD

Johns Hopkins University, Baltimore, MD, USA

Genetically Based Targeting of Convergent Signaling Nodes to Treat Pathological Pain

Session Details • Bio

Eric Villalón, PhD

Eric Villalón, PhD

Loyola University Chicago, Maywood, IL, USA

Molecular Targeting of the Neuronal Membrane Proteasome to Modulate Peripheral Sensory Signaling

Session Details • Bio